GILEAD SCIENCES, INC. Total Long-Term Debt
GILEAD SCIENCES, INC. (GILD) had Total Long-Term Debt of $26.25 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-06
- 2026-06-30: Long-term Debt $26.25B.
- 2026-03-31: Long-term Debt $22.17B.
- 2025-12-31: Long-term Debt $24.94B.
- 2025-09-30: Long-term Debt $24.94B.
| Period end | Long-term Debt | Long-term Debt as first filed |
|---|---|---|
| 2026-06-30 | $26.25B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $22.17B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $24.94B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $24.94B 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $24.95B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $24.95B 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $26.71B 10-K · filed 2026-02-24 | |
| 2024-09-30 | $23.25B 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $23.35B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $25.19B 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $24.99B 10-K · filed 2025-02-28 | |
| 2023-09-30 | $24.98B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $25.25B 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $25.24B 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $25.23B 10-K · filed 2024-02-23 | |
| 2022-09-30 | $25.22B 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $26.22B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $26.21B 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $26.70B 10-K · filed 2023-02-22 | |
| 2021-09-30 | $27.69B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $30.18B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $30.17B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $31.40B 10-K · filed 2022-02-23 | $30.50B 10-K · filed 2021-02-25 |
| 2018-09-30 | $27.32B 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $29.06B 10-Q · filed 2018-08-06 | |
| 2017-12-31 | $33.54B 10-Q · filed 2018-11-06 | |
| 2015-12-31 | $22.18B 10-K · filed 2016-02-24 | |
| 2015-03-31 | $12.36B 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $12.40B 10-K · filed 2016-02-24 | |
| 2014-09-30 | $9.41B 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $9.50B 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $9.80B 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $6.64B 10-K · filed 2015-02-25 | $6.64B 10-K · filed 2014-02-25 |
| 2013-09-30 | $7.31B 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $7.34B 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $8.00B 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $8.22B 10-K · filed 2014-02-25 | |
| 2012-09-30 | $8.77B 10-Q · filed 2012-11-06 | |
| 2011-12-31 | $7.61B 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |